IoT, digital twins, big data, predictive analytics, AI and quantum computing are among the exciting developments with ongoing unrealized potential for supply chain innovation. To fully utilize the power of data, firms must react to it in real time, which is why Controlant’s use of IoT technology has been so effective. There’s an important distinction to be made between visibility and traceability, and between intelligence and decision making, and pharma supply chain leaders cannot tap into the full potential of process automation without high-quality, real-time, GXP-validated data — as well as the architecture and data model to support it.
Emerging technologies continue to advance supply chain visibility, but what we’re seeing more and more is that a deliberate and intense focus on specific business outcomes that pharmaceutical supply chain leaders are trying to achieve is vital to realizing the potential of these technologies. Without understating this potential, the real value is in adoption, where one key driver is partner and data interconnectedness. Companies are built around different types of ecosystems that influence how they deal with complexity and change. This matters when adopting new technologies, with an enterprise-centric ecosystem helping companies leverage interconnectivity, maximize technological and operational flexibility, and increase the focus on where innovative capabilities can add the most value.
Global pharma companies today need to be agile: to adapt at a moment’s notice without risking their ability to have complete visibility and control over their supply chain. This is key to what we do at Controlant with our Aurora Platform, devices and services, applying and developing new technologies to give pharmaceutical companies real-time decision-making capability based on validated data and to help them secure the kind of technical and operational flexibility they need to be successful going forward.